Krystal Biotech saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an increase from 68 to 73.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's unique RS Rating measures market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History reveals that the best stocks tend to have an 80 or higher RS Rating in the early stages of their moves. See if Krystal Biotech can continue to rebound and hit that benchmark.
While it's not currently an ideal time to buy shares, see if the stock goes on to establish and enter a buying range in heavy volume.
Earnings growth rose last quarter from 0% to 407%. But revenue gains fell from 879% to 116%. The company is expected to report its latest earnings and sales numbers on or around May 6.
The company holds the No. 11 rank among its peers in the Medical-Biomed/Biotech industry group. GeneDx Holdings, ADMA Biologics and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
